MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enha…

Benzinga

New York

United States

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - Telix Pharmaceuticals (NASDAQ:TLX)

Ad Fontes Media

Media Bias/Fact Check

MELBOURNE, Australia and INDIANAPOLIS, IN, USA I January 12, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance …

pipelinereview

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - Pipelinereview

Telix Pharmaceuticals has announced an asset purchase agreement with antibody engineering firm ImaginAb, Inc, marking the expansion of its capabilities in precision medicine and therapeutic innovation.

Australian Manufacturing

Telix secures advanced biologics technology platform in strategic deal - Australian Manufacturing

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024). 
Sustained revenue growth 
Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million)[1], represents an increase of 46% over the prior year corresponding quarter (Q4 2023…

Macau Business

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Telix expands its cancer therapeutics portfolio with ImaginAb's next-gen drug candidates and biologics platform, including advanced antibody engineering technology and research facility.

stocktitan.net

Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enha…

WDC TV News

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform By Investing.com

January 13, 2025 02:08 ET  | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024). Sustained revenue growth Q4 2024 unaudited […]

ADKhabar

Telix Pharmaceuticals Ltd. has reached a deal to acquire a portfolio of potential imaging agents and other assets for up to $185 million, the company announced Monday. Inglewood, California-based biotechnology company ImaginAb is the seller, unloading a pipeline of drug candidates, technology platform and research facility. Telix noted that the acquired assets allow for “highly [...]

ramaonhealthcare.com

Telix Pharmaceuticals to acquire portfolio of imaging-related assets for up to $185M – RamaOnHealthcare

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance…

vir.com.vn

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix Pharmaceuticals Ltd (ASX:TLX) is adding to its portfolio of early-stage drug candidates, in addition to a suite of other assets, through a $73 million asset buy agreement with antibody engineering company ImaginAb, Inc. A further $299 million will also be due (in cash or equity) once Telix hits specific key development and commercial milestones after the deal is struck. The purchased drug candidates can be described as ‘next generation,’ i…

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - Telix Pharmaceuticals (NASDAQ:TLX)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics